Theriva Biologics, Inc.
Theriva Biologics is a clinical-stage company developing therapeutics for cancer and related diseases. Its oncology platform uses oncolytic viruses, which are designed to infect and kill tumor cells and stimulate an anti-tumor immune response. Its lead candidate, VCN-01, is an engineered adenovirus that expresses PH20 hyaluronidase to help the virus and other therapies penetrate tumors. VCN-01 is being studied for solid tumors, including metastatic pancreatic cancer and retinoblastoma, and can be used alone or with cancer therapies such as chemotherapy and immunotherapy. Theriva previously developed gastrointestinal disease candidates SYN-004 and SYN-020. Under a February 2026 license agreement, Rasayana Therapeutics holds an exclusive worldwide license to research, develop, manufacture and commercialize products including SYN-020 and assumes their development and commercialization costs. Theriva is exploring licensing or partnering options for SYN-004. The company is headquartered in Rockville, Maryland.
No SEC Form 4 filings for $TOVX in the last 30 days.
See all $TOVX insider activity →Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. - Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along w
Theriva™ Biologics (NYSE American: TOVX) announced the publication of VIRAGE Phase 2b trial results for VCN-01 in metastatic pancreatic cancer in Nature Medicine. The study showed improved survival and response rates when VCN-01 was combined with standard chemotherapy. Theriva is now evaluating more frequent dosing in the VIRAGE2 Phase 2a trial and exploring VCN-01 for pediatric retinoblastoma.
Theriva Biologics (NYSE American: TOVX) reported Q2 2026 results and said first patients were dosed in the VIRAGE2 Phase 2a trial testing more frequent VCN-01 dosing in metastatic PDAC. The company reported $11.3M cash as of June 30, 2026. General and admin expenses fell to $2.0M and R&D to $1.3M.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TOVX (Theriva Biologics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TOVX coverage spans financial news, technology and mergers & acquisitions.
The divestiture removes a non‑core asset but provides cash and future milestone upside, likely leading to modest downside pressure on the stock.
Positive Phase 2b data suggest survival benefit, likely driving buying interest.
Near-term catalyst is clinical execution (VIRAGE2 enrollment and early safety/pharmacodynamic readouts), supported by disclosed cash runway.
New clinical dosing milestone (first patients dosed) plus cash runway disclosure into Q1 2027 supports near-term risk framing for TOVX.
First dosing is a concrete clinical execution milestone that can improve near-term sentiment and de-risk trial progression, but efficacy remains unproven.
AlphAI scores every news story that mentions TOVX with an AI model for sentiment and relevance, and aggregates insider trades from Theriva Biologics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. - Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along w
2 min readTheriva™ Biologics (NYSE American: TOVX) announced the publication of VIRAGE Phase 2b trial results for VCN-01 in metastatic pancreatic cancer in Nature Medicine. The study showed improved survival and response rates when VCN-01 was combined with standard chemotherapy. Theriva is now evaluating more frequent dosing in the VIRAGE2 Phase 2a trial and exploring VCN-01 for pediatric retinoblastoma.
2 min readTheriva Biologics (NYSE American: TOVX) reported Q2 2026 results and said first patients were dosed in the VIRAGE2 Phase 2a trial testing more frequent VCN-01 dosing in metastatic PDAC. The company reported $11.3M cash as of June 30, 2026. General and admin expenses fell to $2.0M and R&D to $1.3M.
4 min readTheriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve tr
4 min readTheriva Biologics (NYSE American: TOVX) said the first patient was dosed in its VIRAGE2 Phase 2a trial testing more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma with gemcitabine/nab-paclitaxel. Enrollment is expected to finish in H2 2026, with initial data in Q3 2027.
4 min readTheriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to 2020 Stock Incentive Plan On August 3, 2026, Theriva Biologics, Inc. (the “Company”) held its 2026 Annual Mee
2 min readTheriva Biologics (TOVX) said Spain’s AEMPS authorized its VIRAGE2 Phase 2a trial to test more frequent dosing of VCN-01 with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. The trial aims to assess tolerability and whether repeated dosing affects VCN-01 levels, building on VIRAGE results.
4 min readTheriva Biologics (NYSE American: TOVX) said Spain’s AEMPS authorized it to start the VIRAGE2 Phase 2a trial of zabilugene almadenorepvec (VCN-01) with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer. VIRAGE2 will test feasibility of at least 3 VCN-01 doses 2 months apart in 6 patients; primary endpoints are safety and VCN-01 viral genome levels.
2 min readTheriva Biologics is holding a special stockholder meeting on June 5, 2026, to approve the issuance of up to 16,184,560 shares of common stock upon the exercise of previously issued warrants at $0.54 per share. This approval could generate approximately $8.7 million in gross proceeds for the company, though it would dilute existing shareholders. Shareholders will also vote on adjourning the meeting if more votes are needed for the warrant exercise proposal.
3 min readMaxim Group has upgraded Theriva Biologics (NYSE:TBIO) from a Hold rating to a Buy rating. The firm also set a new price target of $9.00 for the company's stock. This upgrade suggests a positive outlook on Theriva Biologics' future performance.
3 min read